AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 201 min read$KROS

Cho Esther sold $46K of KROS

Cho Esther (Chief Legal Officer) sold 4,485 shares of Keros Therapeutics, Inc. (KROS) at $10.29 on 2026-08-18.

Original reporting
SEC EDGAR · Cho Esther
Published Aug 20, 2026, 8:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 20, 2026, 8:16 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$KROS
Neutral
high confidence
Mentioned
$KROS
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$KROSNeutralLow
01

Why it matters

The sale is modest and unlikely to affect Keros Therapeutics' valuation.

02

Market read

Routine insider sale with limited trading relevance.

03

What to watch

Potential upcoming corporate events not disclosed could affect insider behavior.

Relevance 3/10Novelty 2/10Timing: filed today

Background

Form 4 filings disclose insider trades; analysts monitor for material signals.

Company-level read

Ticker impact

$KROSNeutralHigh confidence
Context

Chief Legal Officer sold 4,485 shares for $46,150, reducing her stake to 35,770 shares.

Expected impact

Minimal short-term price pressure; unlikely to move the stock materially.

Evidence & confidence

The transaction is a routine Form 4 filing with a small dollar amount relative to market cap.

Market effects

Sector

No broader sector impact; isolated insider transaction.

Regional

None; company is US-listed biotech with limited regional relevance.

Global

None

Counterpoint

What could challenge this read

The sale could be unrelated to company outlook; investors may ignore.

Key entities

  • Officer
    Cho Esther

    Chief Legal Officer of Keros Therapeutics

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

KROS insider trading history →

Related articles

SEP 28
$KROSMedAI 8/10

Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD

Keros Therapeutics, Inc. (KROS) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD • Initial data expected in the first half of 2027 LEXINGTON, Mass., September 28, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: K

SEC EDGAR 8-K2 min